MARC record from Internet Archive

LEADER: 14381cam 2200613 a 4500
001 ocm35262249
003 OCoLC
005 20200725231033.0
008 960805s1997 maua b 001 0 eng
010 $a 96030911
040 $aDNLM/DLC$beng$cDLC$dNLM$dC#P$dBAKER$dBTCTA$dYDXCP$dTULIB$dBDX$dOCLCO$dOCLCF$dOCLCQ$dOCLCO$dOCLCA$dSAR
016 7 $a9612122$2DNLM
020 $a0817638792$q(hard ;$qacid-free paper)
020 $a9780817638795$q(hard ;$qacid-free paper)
020 $a3764338792$q(hard ;$qacid-free paper)
020 $a9783764338794$q(hard ;$qacid-free paper)
035 $a(OCoLC)35262249
050 00 $aRC523$b.A3967 1997
060 00 $a1996 L-901
060 10 $aWT 155$bA47881 1997
082 00 $a618.97/6831$220
245 00 $aAlzheimer disease :$bfrom molecular biology to therapy /$cRobert Becker, Ezio Giacobini, editors ; with the editorial assistance of Joyce M. Barton, and production assistance of Mona Brown.
260 $aCambridge, MA, U.S.A. :$bBirkhäuser,$c©1997.
300 $axiv, 613 pages :$billustrations ;$c24 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
490 1 $aAdvances in Alzheimer disease therapy
504 $aIncludes bibliographical references and indexes.
505 00 $tCriteria for the Clinical Diagnosis of Alzheimer's Disease: Transcultural Aspects /$rLuigi Amaducci and Marzia Baldereschi --$tClinical And Neuropathological Findings from Cerad /$rJohn C. Morris --$tDifferentiating Alzheimer Disease and Vascular Dementia: Reframing the Question /$rHelena Chui, Qian Zhang and Jeff Victoroff ... --$tBasis of Structural Alzheimer Disease and Some Pathogenic Concepts /$rRobert D. Terry --$tRegional Distribution of Neuropathological Changes in Alzheimer's Disease /$rConstantin Bouras, Pandelis Giannakopoulos and Philippe G. Vallet --$tAlzheimer Neurofibrillary Degeneration: A Feasible and Key Target for Therapeutics /$rKhalid Iqbal, Alejandra del C. Alonso and Cheng-Xin Gong ... --$tDiabetes and Dementia: A Retrospective Neuropathologic Study of Old Diabetics Compared to Non-Diabetic Controls /$rJean-Pierre Michel, Pius Muller and Gabriel Gold ... --$tIsoform-Specific Metabolism of Apolipoprotein E: Implications for Alzheimer's Disease /$rWarren J. Strittmatter --$tApolipoprotein E4 and Cholinergic Activity in Alzheimer's Disease /$rJudes Poirier, Isabelle Aubert and Maire-Claude Delisle ... --$tNew Focus on Cytoskeletal Therapy in Alzheimer's Disease /$rHugo Geerts, Rony Nuydens and Mirjam de Jong ... --$tNovel Cathepsin D Inhibitors Prevent the [beta]-Secretase-Derived Intracellular Formation of a 12 kDA Potentially Amyloidogenic Product in Human Cells /$rNathalie Chevallier, Philippe Marambaud and Jean-Pierre Vincent ... --$tCellular and Test Tube Models of Amyloid-[beta] Formation /$rHenryk M. Wisniewski, Janusz Frackowiak and Bozena Mazur-Kolecka ... --$tEffects of [beta]-Amyloid (1-40) Peptide Injection in the Nucleus Basalis /$rGiancarlo Pepeu, Lisa Giovannelli and Fiorella Casamenti ... --$t[Beta]-Amyloid Precursor Protein -- Role in Cognitive Brain Function? /$rGerda S. Huber, Jean-Luc Moreau and James R. Martin ... --$tPeptides Inhibitor of Amyloidogenesis in Alzheimer's Disease /$rClaudio Soto, Frances Prelli and Blas Frangione ... --$tApoptosis and Alzheimer's Disease: A Self-Assembly and the Initiation of Apoptosis by Plasma Membrane Receptor Cross-Linking /$rC. W. Cotman, D. H. Cribbs and J. H. Su --$tNMDA Receptor Dysfunction in Alzheimer's Disease /$rJohn Olney, David Wozniak and Masahiko Ishimaru ... --$tRole of Neuron-Glia Interactions in Brain Energy Metabolism: Implications for Neurodegenerative Disorders /$rPierre J. Magistretti, Philippe Bittar and Luc Pellerin --$tNeurotrophins, Growth Factors and Mimetic Agents as Neuroprotectors in the Treatment of Alzheimer's Disease /$rAlvin J. Glasky, Ronald F. Ritzmann and Michel P. Rathbone ... --$tCortical Synaptogenesis and Behavioural Consequences in CNS Lesioned Animals Receiving Neurotrophic Factor Therapy /$rA. Claudio Cuello --$tAPP Knockout and APP Over-Expression in Transgenic Mice /$rHui Zheng, Gurparkash Singh and Minghao Jiang ... --$tAlpha2c-Adrenoceptor Overexpressing Mice as a Model to Study Cognitive Functions of Alpha2-Adrenoceptors /$rMarkus Bjorklund, Minna Riekkinen and Paavo Riekkinen, Jr. ... --$t[Beta]-APP-751 Transgenic Mice: Deficits In Learning And Memory /$rPaula M. Moran, Paul C. Moser and Linda S. Higgins ... --$tCentral and Peripheral Consequences of Cholinergic Imbalance in Alzheimer's Disease /$rDaniela Kaufer-Nachum, Alon Friedman and Meira Sternfeld ... --$tAnatomy of Monoaminergic-Cholinergic Interactions in the Primate Basal Forebrain /$rJohn F. Smiley and M.-Marsel Mesulam --$tPharmacological Induction of Cholinergic Hypofunction as a Tool for Evaluating Cholinergic Therapies /$rIsrael Hanin --$tRational Design of New Acetylcholinesterase Inhibitors /$rMario Brufani and Luigi Filocamo --$tAdvances in Understanding Cholinergic Brain Neurons: Implications in the Use of Citicoline (CDP Choline) to Treat Stroke /$rRichard J. Wurtman, Bobby W. Sandage, Jr. and Steven Warach --$tCholinesterase Inhibitors Do More than Inhibit Cholinesterase /$rEzio Giacobini --$tLong-Term Tacrine Treatment: Effect on Nursing Home Placement and Mortality /$rStephen Gracon, Fraser Smith and Toni Hoover ... --$tCholinesterase Inhibitors: An Overview of Their Mechanisms of Action /$rAlbert Enz and Philipp Floersheim --$tPreclinical Pharmacology of Metrifonate: A Promise of Alzheimer Therapy /$rBernard H. Schmidt, Volker C. Hinz and Arjan Blockland ... --$tEptastigmine: A Cholinergic Approach to the Treatment of Alzheimer's Disease /$rBruno P. Imbimbo --$tPhenserine: A Selective, Long-Acting and Brain-Directed Acetylcholinesterase Inhibitor Affecting Cognition and [beta]-APP Processing /$rNigel H. Greig, Donald K. Ingram and William C. Wallace ... --$tOverview of the Development of SDZ ENA 713: A Brain Selective Cholinesterase Inhibitor /$rRavi Anand, Richard D. Hartman, Peggy E. Hayes and Marguirguis Gharabawi --$tPreclinical and Clinical Progress with Huperzine A: A Novel Acetylcholinesterase Inhibitor /$rYifan Han and Xican Tang --$tP11467: An Orally-Active Acetylcholinesterase Inhibitor and [alpha][subscript 2]-Adrenoceptor Antagonist for Alzheimer's Disease /$rHugo M. Vargas, Craig P. Smith and Mary Li ... --$tCholinesterase Inhibitors as Therapy in Alzheimer's Disease: Benefit to Risk Considerations in Clinical Application /$rRobert E. Becker, Pamela Moriearty and Latha Unni ... --$tMolecular Histochemistry of Nicotinic Receptors in Human Brain /$rHannsjorg Schroder, Andrea Wevers and Elke Happich ... --$tNicotinic Cholinergic System and [beta]-Amyloidosis /$rJennifer A. Court, Stephen Lloyd and Robert H. Perry ... --$tRJR-2403: A CNS-Selective Nicotinic Agonist with Therapeutic Potential /$rPatrick M. Lippiello, Merouane Bencherif and William S. Caldwell ... --$tABT-089: An Orally Effective Cholinergic Channel Modulator (ChCM) with Cognitive Enhancement and Neuroprotective Action /$rStephen P. Arneric, Anthony W. Bannon and Jorge D. Brioni ... --$tBiochemistry, Pharmacodynamics and Pharmacokinetics of CI-1002: A Combined Anticholinesterase and Muscarinic Antagonist /$rMark R. Emmerling, Michael J. Callahan and Wiliam J. Lipinski ... --$tMuscarinic Partial Agonists in the Symptomatic Treatment of Alzheimer's Disease /$rRajinder Kumar, Eve Cedar and Michael S. G. Clark ... --$tSafety and Clinical Efficacy of S12024 in Patients with Mild to Moderate Alzheimer's Disease /$rHerve Allain, David Guez and Eric Neuman ... --$tPharmacological Characterization of PD151832: An M1 Muscarinic Receptor Agonist /$rRoy D. Schwarz, Michael J. Callahan and Robert E. Davis ... --$tNovel M1 Agonists: From Symptomatic Treatment Towards Delaying the Progression of Alzheimer's Disease /$rAbraham Fisher, Rachel Haring and Zippora Pittel ... --$tFree Radical Scavengers Block the Actions of [beta]-Amyloid on Neurons in Tissue Culture /$rJ. Steven Richardson and Yan Zhou --$tTherapeutic Strategies in Alzheimer's Disease /$rM. Flint Beal --$tNew Synthetic Bioantioxidants: Acetylcholinesterase (AChE) /$rFaina I. Braginskaya, Elena M. Molochkina and Olga M. Zorina ... --$tRationale to Treat Alzheimer's Disease with Selegiline -- Can We Prevent the Progression of the Disease? /$rPaavo J. Riekkinenm, Sr, Keijo J. Koivisto and Eeva-Liisa Helkala ... --$tInflammatory Processes: Anti-Inflammatory Therapy /$rPaul S. Aisen, Deborah B. Marin and Kenneth L. Davis --$tPropentofylline: Preclinical Data /$rKarl A. Rudolphi --$tPropentofylline (HWA 285): A Subgroup Analysis of Phase III Clinical Studies in Alzheimer's Disease And Vascular Dementia /$rBarbara Kittner --$tAnapsos: New Therapeutic Strategies for Neurodegeneration and Brain Aging with Neuroimmunotrophic Factors /$rX. Anton Alvarez, Raquel Zas and Raquel Lagares ... --$tClinical Trials to Prevent Alzheimer's Disease in a Population At-Risk /$rMichael Grundman and Leon J. Thal --$tEffects on Decline or Deterioration /$rSerge Gauthier, Judes Poirier and Julian Gray --$tBridging Study: Optimizing the Dose for PhaseII/III /$rNeal R. Cutler and John J.
505 00 $tSramek --$tAssessment of Therapeutic Strategies for Slowing Progression of Alzheimer's Disease /$rMichael J. Pontecorvo and Wim Parys
505 80 $tPotential for Progress in the Therapeutics of Alzheimer's Disease: Unanswered Questions /$rKenneth L. Davis --$tAlzheimer's Disease Assessment Scale: Modifications That Can Enhance its Use in Future Clinical Trials /$rRichard C. Mohs, Deborah Marin and Cynthia R. Green ... --$tItem Pool to Assess Activities of Daily Living in Alzheimer's Disease /$rDouglas R. Galasko and David Bennett --$tSevere Impairment Battery: A Potential Measure for Alzheimer's Disease Clinical Trials /$rFrederick A. Schmitt, J. Wesson Ashford and Steven Ferris ... --$tValidity and Reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression Of Change (ADCS-CGIC) /$rLon S. Schneider, Jason T. Olin and Rachelle S. Doody ... --$tAdvantages of the "Time-Index" Method for Measurement of Alzheimer Dementia: Assessment of Metrifonate Benefit /$rJ. Wesson Ashford, Frederick A. Schmitt and Daniel Wermeling ... --$tPET-Studies Using 11C-TZTP Derivatives for the Visualization of Muscarinic Receptors in the Human Brain /$rHenrik Nyback, Christer Halldin, Per Karlsson and Yoshifumi Nakashima ... --$tPET Imaging of Nicotinic Receptors in Alzheimer's Disease: Implication with Diagnosis and Drug Treatment /$rAgneta Nordberg --$tCerebral SPECT Imaging: Advances in Radio-Pharmaceuticals and Quantitative Analysis /$rDaniel O. Slosman and Pierre J. Magistretti --$tIn Vivo Imaging of Anticholinesterase Drugs Used in Alzheimer's Disease /$rB. Tavitian, S. Pappata and F. Branly ... --$tSPECT Scan And Efficacy of Therapy in Alzheimer's Disease /$rJacques Darcourt, Octave Migneco and Philippe Robert ... --$tMRI and Cognitive Markers of Progression and Risk of Alzheimer Disease /$rSteven H. Ferris and Mony J. de Leon --$tBrain Mapping and Transcranial Doppler Ultrasonography in Alzheimer Disease Drug Monitoring /$rRamon Cacabelos, Jose Caamano and Dolores Vinagre ... --$tAPOE Genotype and MRI Volumetry: Implication for Therapy /$rHilkka S. Soininen, Maarit Lehtovirta and Mikko P. Laakso ... --$tGroup Psychotherapy /$rJose Guimon and Elisabeth Basaguren --$tNon Cognitive Symptoms in Alzheimer's Disease /$rPhilippe H. Robert, Charles Henri Beau and Valerie Migneco ... --$tDepression And Alzheimer's Disease /$rCarl-Gerhard Gottfries --$tPsychomotor Therapy and Alzheimer's Disease /$rJacques Richard, Philippe Bovier and Jean-Philippe Bocksberger --$tBehavioral Techniques for Treatment of Patients with Alzheimer's Disease /$rLinda Teri --$tTreatment of Psychosocial Disturbances /$rJean-Marie Leger, Jean-Pierre Clement and Sandrine Paulin --$tSerotoninergic Symptomatology in Dementia /$rValerie M. Aubin-Brunet, Charles H. Beau and Genevieve Asso ... --$tInformed Consent and Alzheimer Disease Research: Institutional Review Board Policies And Practices /$rTheodore R. LeBlang and Jean L. Kirchner --$tLegal Issues in Alzheimer Disease Research in France /$rAlain Garay --$tEthical Problems in Therapeutic Research in Alzheimer's Disease Patients /$rStephanie Thibault, Lucette Lacomblez and Christian Derouesne --$tMaking Consent Work in Alzheimer Disease Research /$rGeorge J. Agich --$tIndustry Perspectives on the Marketing of Anti-Alzheimer Disease Therapy /$rRobert van der Mark --$tCODEM: A Longitudinal Study on Alzheimer Disease Costs /$rMarco Trabucchi, Karin M. Ghisla and Angelo Bianchetti --$tHealth Economic Aspects of Alzheimer's Disease and the Implications for Drug Development and Pricing /$rM. Hardens --$tInternational Working Group for the Harmonization of Dementia Drug Guidelines: A Progress Report /$rPeter J. Whitehouse --$tDeveloping Safe and Effective Antidementia Drugs /$rPaul D. Leber --$tJapanese Perspective on the Work of the International Group on Harmonization of Drug Guidelines /$rAkira Homma --$tRonald and Nancy Reagan Research Institute of The Alzheimer's Association /$rZ. S. Khachaturian and T. S. Radebaugh.
650 0 $aAlzheimer's disease$xChemotherapy.
650 0 $aCholinesterase inhibitors$xTherapeutic use.
650 0 $aAlzheimer's disease$xMolecular aspects.
650 0 $aAlzheimer's disease$xTreatment.
650 12 $aAlzheimer Disease$xtherapy.
650 7 $aAlzheimer's disease$xChemotherapy.$2fast$0(OCoLC)fst00806536
650 7 $aAlzheimer's disease$xMolecular aspects.$2fast$0(OCoLC)fst00806550
650 7 $aAlzheimer's disease$xTreatment.$2fast$0(OCoLC)fst00806591
650 7 $aCholinesterase inhibitors$xTherapeutic use.$2fast$0(OCoLC)fst00858451
700 1 $aBecker, Robert E.
700 1 $aGiacobini, Ezio.
830 0 $aAdvances in Alzheimer disease therapy.
938 $aBaker & Taylor$bBKTY$c169.00$d169.00$i0817638792$n0002905079$sactive
938 $aBrodart$bBROD$n50292412$c$98.50
938 $aBaker and Taylor$bBTCP$n96030911
938 $aYBP Library Services$bYANK$n1335065
029 1 $aAU@$b000012664736
029 1 $aHR0$bG05268984
029 1 $aNLM$b9612122
029 1 $aYDXCP$b1335065
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 143 OTHER HOLDINGS